(MENAFN- GlobeNewsWire - Nasdaq) The Global Biotechnology Market is projected to surge from US$ 4.26 trillion in 2024 to US$ 1.40 trillion by 2033, with a robust CAGR of 13.1%. This growth is driven by advances in genetic engineering, rising biopharmaceutical demand, and broadening biotech applications across agriculture, healthcare, and industry. Key markets like the U.S., Germany, India, and Saudi Arabia are fostering innovation through government support and strategic investments. Leading players include Lonza, Amgen, and Syngenta. However, challenges like regulatory hurdles and high R&D costs persist, impacting the biotech landscape.Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Biotechnology Market - Therapeutic Innovations & Forecast 2025-2033" report has been added to ResearchAndMarkets's offering.
Global Biotechnology Market is anticipated to grow to US$ 1.40 trillion by 2033, from US$ 4.26 trillion in 2024, with an expected CAGR of 13.1% from 2025 to 2033. Advancements in genetic engineering, increasing demand for biopharmaceuticals, R&D investment, and widening applications in agriculture, healthcare, and industrial sectors are driving growth, as innovation is revolutionized across global scientific and medical arenas.
![]()
Biotechnology'spopularity has escalated in the last few decades because of advances in genomics, personalized medicine, and sustainable agriculture. In the field of medicine, biotechnology has enabled revolutionary progress in curing such illnesses as cancer, diabetes, and rare genetic diseases. The COVID-19 pandemic further fueled interest and investment in biotech, particularly in vaccine production and testing. Moreover, increased global food needs and environmental issues have spurred biotechnology use for improving crops and reducing waste. Governments and private entities across the globe are investing in biotech research and start-ups, making it one of the fastest-growing and most revolutionary industries in the 21st century.
Growth Drivers in the Global Biotechnology Market
Advances in Genomics and Personalized Medicine
Genome sequencing and gene-editing technologies, including CRISPR, are transforming personalized medicine. Personalized therapies are enhancing the treatment of cancer, rare genetic diseases, and chronic diseases. Declining prices for whole-genome sequencing open up these technologies to more customers. Pharmaceutical and biotech companies increasingly seek to build precision medicine pipelines, driving innovation and commercial interest.
With regulatory frameworks evolving to enable these breakthroughs, investment and adoption are quickening, driving the biotechnology market forward. In December 2023, DBT (the Department of Biotechnology) and BIRAC (Biotechnology Industry Research Assistance Council) announced the commercialization of more than 14 cutting-edge biotechnology products developed by well-established firms and start-ups in multiple industries like medical devices, healthcare diagnostics, agriculture, and industrial biotechnology.
Increasing Demand for Biopharmaceuticals and Vaccines
Increased demand for biologics such as monoclonal antibodies, recombinant proteins, cell and gene therapies, and vaccines is driven by global health emergencies, an aging population, and the incidence of chronic conditions. Investment in biopharma R&D and both public and private investment in biopharma R&D are growing, fueled by the success of mRNA COVID vaccines, with interest in mRNA-based cancer and infectious disease treatments.
The demand for scalable and efficient manufacturing of biologics drives biotech infrastructure growth and market expansion globally. January 2025, Esphera SynBio, a pre-clinical stage synthetic biology firm, has initiated a new project that is focused on improving the effectiveness of mRNA vaccines. The firm will use its patented technology to design mRNA vaccines that, when delivered, direct patient cells to create altered nanomedicines.
Environmental and Industrial Biotechnology Applications
Outside of medicine, biotechnology's uses in agriculture, biofuels, and waste treatment are gaining strength. Microbial biofertilizers and GMO crops enhance sustainable food production, with enzyme-based industrial processes minimizing the use of chemicals and waste. Bioremediation harnesses microbes to detoxify pollutants, and bio-based materials offer sustainable alternatives. Regulation focus on sustainability, coupled with consumers' push for green products, is driving investment into industrial biotechnology, releasing new streams of revenue and market opportunities.
The National Biopharma Mission (NBM)-Innovate in India (i3), led by the Department of Biotechnology and implemented by BIRAC, aims to enhance India's biopharmaceutical capabilities through industry-academia collaboration. With a budget of $250 million (50% co-funded by the World Bank), it supports 101 projects involving over 150 organizations and 30 MSMEs. The mission has established 11 shared facilities for testing and manufacturing, generating over 1,000 jobs, including 304 scientists. Furthermore, the Genome India Programme, a young genome sequencing project designed to sequence 10,000 genomes, is going to impact healthcare policy in the future.
Global Biotechnology Market Challenges
Regulatory Barriers and Ethical Issues
Biotech is subject to stringent regulatory oversight because of health, safety, and environmental concerns. Delayed approval times and heterogenous requirements between jurisdictions (e.g., FDA, EMA) add cost and slow product launches. Ethical controversy surrounding gene editing, GMOs, and data protection makes public opinion and policy difficult. Lack of consistency in regulations has the potential to cause market uncertainty, compelling companies to invest significant resources in compliance and lobbying, which can divert attention away from R&D and innovation objectives.
High Investment Risk and R&D Costs
It takes a lot of investment in R&D, clinical trials, and manufacturing scale-up to develop biotech products. Failure rates are high, particularly in late-stage clinical development. Funding has become highly competitive, and investors anticipate notable milestones before they will invest capital. Smaller biotech ventures are at risk financially if clinical failures happen. Such pressures in funding can constraint innovation and postpone or abort promising initiatives, particularly when being both scientific aspiration and commercial viability are balanced.
Key Attributes:
CONTACT: CONTACT:
Laura Wood,Senior Press Manager
...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment